Personalizing Anticoagulant and Antiplatelet Therapeutics: A Timely Task

Abstract

In spite of new therapeutics and diagnostics, thrombosis‐related diseases including heart failure and stroke remain the leading cause of death globally and a major healthcare burden. Pharmacogenomic studies may reduce the burden of thrombotic diseases by aiding treatment individualization with the most appropriate anti‐coagulant and anti‐platelet therapeutics. Discovering and validating biomarkers for improved personalized treatment of thrombotic diseases will require massive investment. A concerted dedicated effort built upon a public‐private partnership is warranted for addressing this foremost public health concern.